KR20180031035A - 5-ht2c 수용체 효능제 및 조성물 및 사용 방법 - Google Patents

5-ht2c 수용체 효능제 및 조성물 및 사용 방법 Download PDF

Info

Publication number
KR20180031035A
KR20180031035A KR1020187005698A KR20187005698A KR20180031035A KR 20180031035 A KR20180031035 A KR 20180031035A KR 1020187005698 A KR1020187005698 A KR 1020187005698A KR 20187005698 A KR20187005698 A KR 20187005698A KR 20180031035 A KR20180031035 A KR 20180031035A
Authority
KR
South Korea
Prior art keywords
compound
formula
subject
compounds
azepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187005698A
Other languages
English (en)
Korean (ko)
Inventor
위르크 레만
콘라드 페이히팅거
앨버트 에스. 렌
그레엄 셈플
Original Assignee
아레나 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아레나 파마슈티칼스, 인크. filed Critical 아레나 파마슈티칼스, 인크.
Publication of KR20180031035A publication Critical patent/KR20180031035A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020187005698A 2015-07-31 2016-07-28 5-ht2c 수용체 효능제 및 조성물 및 사용 방법 Withdrawn KR20180031035A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199382P 2015-07-31 2015-07-31
US62/199,382 2015-07-31
PCT/US2016/044426 WO2017023679A1 (en) 2015-07-31 2016-07-28 5-ht2c receptor agonists and compositions and methods of use

Publications (1)

Publication Number Publication Date
KR20180031035A true KR20180031035A (ko) 2018-03-27

Family

ID=56684262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187005698A Withdrawn KR20180031035A (ko) 2015-07-31 2016-07-28 5-ht2c 수용체 효능제 및 조성물 및 사용 방법

Country Status (14)

Country Link
US (4) US10272094B2 (cg-RX-API-DMAC7.html)
EP (1) EP3328835B1 (cg-RX-API-DMAC7.html)
JP (1) JP6789578B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180031035A (cg-RX-API-DMAC7.html)
CN (1) CN108137508B (cg-RX-API-DMAC7.html)
AU (1) AU2016302755B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018001707A2 (cg-RX-API-DMAC7.html)
CA (1) CA3002525A1 (cg-RX-API-DMAC7.html)
EA (1) EA039412B1 (cg-RX-API-DMAC7.html)
HK (1) HK1255850A1 (cg-RX-API-DMAC7.html)
IL (1) IL257107B (cg-RX-API-DMAC7.html)
MA (1) MA42527A (cg-RX-API-DMAC7.html)
MX (1) MX375045B (cg-RX-API-DMAC7.html)
WO (1) WO2017023679A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272094B2 (en) * 2015-07-31 2019-04-30 Arena Pharmaceuticals, Inc. 5-HT2C receptor agonists and compositions and methods of use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110668951B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 一种盐酸司来吉兰的合成工艺
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
US20220410894A1 (en) * 2021-06-29 2022-12-29 Tusimple, Inc. Systems and methods for operating an autonomous vehicle
US12311973B2 (en) 2021-10-14 2025-05-27 Tusimple, Inc. Systems and methods for operating an autonomous vehicle

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180733A (en) * 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
CA2482195A1 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
EA016558B1 (ru) * 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
EP2098512A1 (en) * 2003-10-08 2009-09-09 Eli Lilly & Company Compounds and methods for treating dyslipidemia
WO2011071136A1 (ja) * 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2013133325A1 (ja) * 2012-03-06 2013-09-12 武田薬品工業株式会社 三環性化合物
HK1212684A1 (zh) * 2012-09-14 2016-06-17 AbbVie Deutschland GmbH & Co. KG 三環喹啉和喹喔啉衍生物
US10272094B2 (en) 2015-07-31 2019-04-30 Arena Pharmaceuticals, Inc. 5-HT2C receptor agonists and compositions and methods of use

Also Published As

Publication number Publication date
HK1255850A1 (zh) 2019-08-30
WO2017023679A1 (en) 2017-02-09
MA42527A (fr) 2021-04-07
CA3002525A1 (en) 2017-02-09
US10624900B2 (en) 2020-04-21
US20230055376A1 (en) 2023-02-23
AU2016302755B2 (en) 2020-09-10
MX375045B (es) 2025-03-06
US10272094B2 (en) 2019-04-30
EP3328835B1 (en) 2022-10-12
EA201890402A1 (ru) 2018-09-28
US20200078368A1 (en) 2020-03-12
IL257107A (en) 2018-03-29
CN108137508B (zh) 2021-08-27
BR112018001707A2 (pt) 2018-09-18
EA039412B1 (ru) 2022-01-25
EP3328835A1 (en) 2018-06-06
AU2016302755A1 (en) 2018-03-15
CN108137508A (zh) 2018-06-08
US20180214455A1 (en) 2018-08-02
JP2018522025A (ja) 2018-08-09
NZ739883A (en) 2021-03-26
JP6789578B2 (ja) 2020-11-25
US11395824B2 (en) 2022-07-26
MX2018001380A (es) 2018-06-15
US20200383993A1 (en) 2020-12-10
IL257107B (en) 2021-03-25

Similar Documents

Publication Publication Date Title
US11395824B2 (en) 5-HT2C receptor agonists and compositions and methods of use
KR102275505B1 (ko) 5-ht2c 수용체 효능제 및 조성물 및 사용 방법
US11608339B2 (en) 5-HT2C receptor agonists and compositions and methods of use
JP2018519251A5 (cg-RX-API-DMAC7.html)
TW201605856A (zh) ５－ＨＴｃ受體促效劑
NZ739883B2 (en) 5-ht2c receptor agonists and compositions and methods of use
HK40010293A (en) 5-ht2c receptor agonists and compositions and methods of use
NZ737412B2 (en) 5-ht2c receptor agonists and compositions and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210727

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20221017

WITB Written withdrawal of application